Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

728 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pre-existent NRTI and NNRTI resistance impacts on maintenance of virological suppression in HIV-1-infected patients who switch to a tenofovir/emtricitabine/rilpivirine single-tablet regimen.
Armenia D, Di Carlo D, Calcagno A, Vendemiati G, Forbici F, Bertoli A, Berno G, Carta S, Continenza F, Fedele V, Bellagamba R, Cicalini S, Ammassari A, Libertone R, Zaccarelli M, Ghisetti V, Andreoni M, Ceccherini-Silberstein F, Bonora S, Di Perri G, Antinori A, Perno CF, Santoro MM. Armenia D, et al. Among authors: di perri g, di carlo d. J Antimicrob Chemother. 2017 Mar 1;72(3):855-865. doi: 10.1093/jac/dkw512. J Antimicrob Chemother. 2017. PMID: 27999048
Longitudinal analysis of HIV-1 coreceptor tropism by single and triplicate HIV-1 RNA and DNA sequencing in patients undergoing successful first-line antiretroviral therapy.
Meini G, Rossetti B, Bianco C, Ceccherini-Silberstein F, Di Giambenedetto S, Sighinolfi L, Monno L, Castagna A, Rozera G, D'Arminio Monforte A, Zazzi M, De Luca A; ICONA Foundation Group. Meini G, et al. J Antimicrob Chemother. 2014 Mar;69(3):735-41. doi: 10.1093/jac/dkt426. Epub 2013 Oct 23. J Antimicrob Chemother. 2014. PMID: 24155059 Free PMC article.
Virological response and retention in care according to time of starting ART in Italy: data from the Icona Foundation Study cohort.
d'Arminio Monforte A, Tavelli A, Cozzi-Lepri A, Castagna A, Passerini S, Francisci D, Saracino A, Maggiolo F, Lapadula G, Girardi E, Perno CF, Antinori A; Icona Foundation Study Group. d'Arminio Monforte A, et al. J Antimicrob Chemother. 2020 Mar 1;75(3):681-689. doi: 10.1093/jac/dkz512. J Antimicrob Chemother. 2020. PMID: 31865395
Nevirapine plasma exposure affects both durability of viral suppression and selection of nevirapine primary resistance mutations in a clinical setting.
González de Requena D, Bonora S, Garazzino S, Sciandra M, D'Avolio A, Raiteri R, Marrone R, Boffito M, De Rosa FG, Sinicco A, Di Perri G. González de Requena D, et al. Among authors: di perri g. Antimicrob Agents Chemother. 2005 Sep;49(9):3966-9. doi: 10.1128/AAC.49.9.3966-3969.2005. Antimicrob Agents Chemother. 2005. PMID: 16127084 Free PMC article.
Key questions in antiretroviral therapy: Italian Consensus Workshop (2005).
Carosi G, Torti C, Andreoni M, Angarano G, Antinori A, Bonora S, Borderi M, Castagna A, Castelli F, Cauda R, Chiodo F, D'arminio-Monforte A, De Luca A, Di Perri G, Dianzani F, Filice G, Galli M, Lazzarin A, Maggiolo F, Maserati R, Mazzotta F, Moroni M, Perno CF, Vullo V. Carosi G, et al. Among authors: di perri g. J Antimicrob Chemother. 2006 Jun;57(6):1055-64. doi: 10.1093/jac/dkl113. Epub 2006 Apr 10. J Antimicrob Chemother. 2006. PMID: 16606637
The use of trough ribavirin concentration to predict sustained virological response and haematological toxicity in HIV/HCV-co-infected patients treated with ribavirin and pegylated interferon.
Aguilar Marucco D, Gonzalez de Requena D, Bonora S, Tettoni C, Bonasso M, De Blasi T, D'Avolio A, Sciandra M, Siccardi M, Baietto L, Trentini L, Sinicco A, Cariti G, Di Perri G. Aguilar Marucco D, et al. Among authors: di perri g. J Antimicrob Chemother. 2008 Apr;61(4):919-24. doi: 10.1093/jac/dkn013. Epub 2008 Jan 31. J Antimicrob Chemother. 2008. PMID: 18238889
Two different patterns of mutations are involved in the genotypic resistance score for atazanavir boosted versus unboosted by ritonavir in multiple failing patients.
Santoro MM, Bertoli A, Lorenzini P, Ceccherini-Silberstein F, Gianotti N, Mussini C, Torti C, Di Perri G, Barbarini G, Bini T, Melzi S, Caramello P, Maserati R, Narciso P, Micheli V, Antinori A, Perno CF; CARe Study Group. Santoro MM, et al. Among authors: di perri g. Infection. 2009 Jun;37(3):233-43. doi: 10.1007/s15010-008-8065-4. Epub 2009 Jan 23. Infection. 2009. PMID: 19169632
Is peritoneal fluid a sanctuary site for HIV?
Calcagno A, Rostagno R, Audagnotto S, D'Avolio A, Bonora S, Ghisetti V, Di Perri G. Calcagno A, et al. Among authors: di perri g. J Antimicrob Chemother. 2010 Sep;65(9):2052-3. doi: 10.1093/jac/dkq235. Epub 2010 Jun 23. J Antimicrob Chemother. 2010. PMID: 20573660 No abstract available.
728 results